Leveraging publicly available coronavirus data to identify new therapeutic targets for COVID-19.

Many important questions remain regarding severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the viral pathogen responsible for COVID-19. These questions include the mechanisms explaining the high percentage of asymptomatic but highly infectious individuals, the wide variability in diseas...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Stacy L Sell, Donald S Prough, Harris A Weisz, Steve G Widen, Helen L Hellmich
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/8b4ec04386c941bd88ccab2052e186c1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8b4ec04386c941bd88ccab2052e186c1
record_format	dspace
spelling	oai:doaj.org-article:8b4ec04386c941bd88ccab2052e186c12021-11-25T06:18:59ZLeveraging publicly available coronavirus data to identify new therapeutic targets for COVID-19.1932-620310.1371/journal.pone.0257965https://doaj.org/article/8b4ec04386c941bd88ccab2052e186c12021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0257965https://doaj.org/toc/1932-6203Many important questions remain regarding severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the viral pathogen responsible for COVID-19. These questions include the mechanisms explaining the high percentage of asymptomatic but highly infectious individuals, the wide variability in disease susceptibility, and the mechanisms of long-lasting debilitating effects. Bioinformatic analysis of four coronavirus datasets representing previous outbreaks (SARS-CoV-1 and MERS-CoV), as well as SARS-CoV-2, revealed evidence of diverse host factors that appear to be coopted to facilitate virus-induced suppression of interferon-induced innate immunity, promotion of viral replication and subversion and/or evasion of antiviral immune surveillance. These host factors merit further study given their postulated roles in COVID-19-induced loss of smell and brain, heart, vascular, lung, liver, and gut dysfunction.Stacy L SellDonald S ProughHarris A WeiszSteve G WidenHelen L HellmichPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 9, p e0257965 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Stacy L Sell Donald S Prough Harris A Weisz Steve G Widen Helen L Hellmich Leveraging publicly available coronavirus data to identify new therapeutic targets for COVID-19.
description	Many important questions remain regarding severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the viral pathogen responsible for COVID-19. These questions include the mechanisms explaining the high percentage of asymptomatic but highly infectious individuals, the wide variability in disease susceptibility, and the mechanisms of long-lasting debilitating effects. Bioinformatic analysis of four coronavirus datasets representing previous outbreaks (SARS-CoV-1 and MERS-CoV), as well as SARS-CoV-2, revealed evidence of diverse host factors that appear to be coopted to facilitate virus-induced suppression of interferon-induced innate immunity, promotion of viral replication and subversion and/or evasion of antiviral immune surveillance. These host factors merit further study given their postulated roles in COVID-19-induced loss of smell and brain, heart, vascular, lung, liver, and gut dysfunction.
format	article
author	Stacy L Sell Donald S Prough Harris A Weisz Steve G Widen Helen L Hellmich
author_facet	Stacy L Sell Donald S Prough Harris A Weisz Steve G Widen Helen L Hellmich
author_sort	Stacy L Sell
title	Leveraging publicly available coronavirus data to identify new therapeutic targets for COVID-19.
title_short	Leveraging publicly available coronavirus data to identify new therapeutic targets for COVID-19.
title_full	Leveraging publicly available coronavirus data to identify new therapeutic targets for COVID-19.
title_fullStr	Leveraging publicly available coronavirus data to identify new therapeutic targets for COVID-19.
title_full_unstemmed	Leveraging publicly available coronavirus data to identify new therapeutic targets for COVID-19.
title_sort	leveraging publicly available coronavirus data to identify new therapeutic targets for covid-19.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/8b4ec04386c941bd88ccab2052e186c1
work_keys_str_mv	AT stacylsell leveragingpubliclyavailablecoronavirusdatatoidentifynewtherapeutictargetsforcovid19 AT donaldsprough leveragingpubliclyavailablecoronavirusdatatoidentifynewtherapeutictargetsforcovid19 AT harrisaweisz leveragingpubliclyavailablecoronavirusdatatoidentifynewtherapeutictargetsforcovid19 AT stevegwiden leveragingpubliclyavailablecoronavirusdatatoidentifynewtherapeutictargetsforcovid19 AT helenlhellmich leveragingpubliclyavailablecoronavirusdatatoidentifynewtherapeutictargetsforcovid19
_version_	1718413936530817024

Leveraging publicly available coronavirus data to identify new therapeutic targets for COVID-19.

Ejemplares similares